https://novapharmanews.com/eu/news/truqap-combo-wins-new-approval-us-pten-deficient-prostate-cancer 2026-06-15T06:22:43.843Z NovaPharmaNews en 2026-06-14T16:33:22.670Z Truqap combo wins new US approval in PTEN-deficient prostate cancer Truqap, capivasertib, abiraterone, prednisone, Oncology https://novapharmanews.com/uploads/articles/truqap-combo-wins-new-approval-us-pten-deficient-prostate-cancer.webp Truqap combo wins new US approval in PTEN-deficient prostate cancer https://novapharmanews.com/eu/news/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc 2026-06-14T22:33:45.261Z NovaPharmaNews en 2026-06-14T12:41:57.231Z FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC capivasertib, Truqap, abiraterone, Zytiga, prednisone, prednisolone, abiraterone acetate, prostate cancer, metastatic androgen pathway modulation-naive prostate cancer, metastatic androgen pathway modulation-sensitive prostate cancer https://novapharmanews.com/uploads/articles/fda-approves-capivasertib-abiraterone-prednisone-pten-deficient-mhspc.webp FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC https://novapharmanews.com/eu/news/china-big-pharma-essential-rd-partner 2026-06-15T04:32:24.939Z NovaPharmaNews en 2026-06-14T12:41:56.401Z China Becomes Big Pharma's Essential R&D Partner https://novapharmanews.com/uploads/articles/china-big-pharma-essential-rd-partner.webp China Becomes Big Pharma's Essential R&D Partner https://novapharmanews.com/us/news/hfma-conference-affordability-friction-high-hospital-costs 2026-06-14T18:08:48.759Z NovaPharmaNews en 2026-06-13T08:04:51.564Z HFMA conference: Affordability was the focus, but fixes remained unclear https://novapharmanews.com/uploads/articles/hfma-conference-affordability-friction-high-hospital-costs.webp HFMA conference: Affordability was the focus, but fixes remained unclear